The research, led by Gonghua Wu, Huan Xu, and Xing Zhao of the West China School of Public Health at Sichuan University, together with collaborators at Sun Yat-sen University, Wuhan University, and West China Hospital, addresses a critical question in global cardiovascular health: whether decades of progress in hypertension detection and drug therapy have actually translated into equitable stroke prevention for entire populations, rather than for treated individuals alone.

Stroke remains one of the leading causes of death and disability worldwide, and high blood pressure is its single most important modifiable risk factor. Decades of randomized trials and individual participant data meta-analyses have established beyond doubt that lowering blood pressure with medication reduces stroke risk across a wide range of baseline blood pressure levels, in both primary and secondary prevention, and in men and women alike. What has been far less clear is how much of this protective effect has actually been “realized” at the population scale, where treatment coverage, adherence, and health system capacity vary enormously between countries and over time.

To quantify this, the team constructed a modelling framework that integrated country-, sex-, age-, and year-specific estimates of hypertension prevalence and treatment coverage with stroke incidence data for adults aged 30 to 79 years in each of 198 countries. The central metric of the analysis is the prevented fraction for the population, or PFP, defined as the proportion of strokes averted under the observed treatment patterns relative to a counterfactual scenario in which no one received antihypertensive treatment. In essence, the PFP answers the question: of all the strokes that would have occurred in a world without treatment, what fraction did existing blood pressure management actually prevent?

This counterfactual approach distinguishes the study from traditional population attributable fraction analyses, which typically estimate the burden caused by a risk factor rather than the burden already removed by an intervention. By anchoring the calculation in real-world treatment coverage drawn from population-representative surveys, including pooled analyses of 1,201 studies with 104 million participants and World Health Organization Global Health Observatory data, the researchers were able to track how the preventive yield of hypertension care evolved across three decades and how it differed by national income group as classified by the World Bank.

The results reveal a story of genuine progress shadowed by profound inequity. Between 1990 and 2019, the median PFP rose from 8.8 percent to 15.9 percent among women and from 5.1 percent to 11.8 percent among men. In practical terms, by the end of the study period, treatment patterns in a typical country were preventing roughly one in six strokes that would otherwise have occurred in women and nearly one in eight in men, compared with a no-treatment counterfactual. The researchers summarized these temporal trends using average annual percentage change and age-period-cohort analyses, statistical techniques that separate the effects of ageing, calendar time, and generational shifts in risk.

Low-income countries recorded the fastest annual increases in realized stroke prevention, a signal that many of the world’s poorest nations have been expanding hypertension treatment from a very low baseline. But the acceleration was not enough to close the gap. In 2019, the prevented fraction in low-income countries remained approximately half that of high-income countries, meaning that even after three decades of catch-up growth, the share of strokes averted by treatment in poorer nations still lagged dramatically behind the levels achieved in wealthier settings. The disparity reflects well-documented barriers in low- and middle-income countries, including limited availability and affordability of blood pressure lowering medicines, gaps in clinical practice guidelines, weaker hypertension care cascades from detection through control, and higher rates of medication nonadherence, all of which have been documented in large international cohorts and recent systematic reviews.

The sex differences in the analysis were consistent and persistent across the entire study period. Women showed higher prevented fractions than men in every year examined, a pattern the authors attribute to a combination of factors including higher rates of hypertension awareness and treatment-seeking among women, differences in healthcare contact, and possibly sex-specific prescription patterns, since systematic reviews have shown that women are sometimes less likely than men to receive cardiovascular medications even when clinically indicated. The finding underscores that although women benefit more from treatment at the population level, the gap itself points to under-treatment of men, who experience higher stroke incidence at middle age in many settings.

Equally striking were the age patterns. The prevented fraction remained low in older adults, the group that carries by far the highest absolute burden of stroke, and was similarly low, or even lower, in adults aged 30 to 34 years. In older populations, the low PFP may reflect therapeutic inertia, multimorbidity, polypharmacy, and the complexity of managing blood pressure in frail patients, factors associated with uncontrolled hypertension in geriatric cohorts. Among the youngest adults, low prevention likely reflects low treatment coverage, since young adults with elevated blood pressure are less likely to be screened, diagnosed, or prescribed medication, even though stroke in young adults carries enormous lifetime consequences in terms of disability, lost productivity, and inability to return to work.

The authors are careful to frame their findings as model-estimated rather than directly observed. The PFP calculation requires linking observed treatment coverage with assumed treatment effects derived from the trial literature, and the resulting estimates carry uncertainty intervals that reflect variability in the underlying data. Nevertheless, the methodology builds on established epidemiological techniques for quantifying deaths averted by existing risk factor prevalence, such as previous analyses of physical activity and mortality using the same prevented fraction framework, and incorporates bias-correction methods developed for population attributable fraction estimation in the presence of confounding.

The implications for global health policy are considerable. The study arrives amid alarming trends in stroke epidemiology: the Global Burden of Disease 2021 analysis found that stroke burden remains enormous and increasingly concentrated in low- and middle-income countries, where ageing populations and rising exposure to risk factors are outpacing gains in prevention. Meanwhile, hypertension prevalence among adults worldwide has remained stubbornly high, with roughly half of hypertensive adults unaware of their condition and the majority not achieving controlled blood pressure. If the realized prevention gap between rich and poor countries persists, the absolute number of preventable strokes in low-income settings will continue to grow.

The findings also add momentum to calls for population-wide strategies that go beyond individual clinical treatment. The World Health Organization’s global report on sodium reduction, along with meta-analyses showing that dietary sodium lowering reduces blood pressure in a dose-dependent manner, supports the case for structural interventions, including reformulation of packaged foods, front-of-pack labeling, and national salt reduction strategies, which evidence suggests can complement pharmaceutical approaches. Because much of the world’s dietary salt comes from manufactured foods, national policies targeting food industry practices may reach populations that clinical care cannot.

For the researchers behind the new analysis, the takeaway is that antihypertensive treatment has corresponded to substantial but uneven model-estimated stroke prevention worldwide. The three-decade trend is genuinely encouraging: millions of strokes have likely been averted, and the trajectory of improvement has been steepest where the need is greatest. But the half-fold gap between low- and high-income countries, the persistent disadvantage among men, and the low prevention achieved in both the oldest and the youngest adults together chart a clear agenda. Closing these gaps, the study suggests, will require not merely more antihypertensive drugs, but stronger health systems that can find, treat, and retain the patients who currently fall through the cracks, from the 30-year-old who never gets screened to the 75-year-old whose blood pressure remains uncontrolled despite a prescription.

The study was funded by the National Natural Science Foundation of China and the Postdoctoral Fellowship Program of the China Postdoctoral Science Foundation. The authors report no competing interests.

The research emerged from the National Institutes of Health-supported Systolic Blood Pressure Intervention Trial Memory and Cognition in Decreased Hypertension Study, commonly referred to as SPRINT MIND. This extensive study encompassed 9,361 participants over the age of 50, recruited from more than 100 clinics across the United States and Puerto Rico. Each participant was randomly allocated to either an intensive treatment group, targeting a systolic blood pressure goal of less than 120 mm Hg, or a standard treatment group with a target of less than 140 mm Hg.

Participants engaged in the study for a median duration of seven years, during which cognitive evaluations were meticulously carried out. These assessments were done both through in-person visits and telephone follow-ups, allowing researchers to classify participants into categories based on their cognitive status. The classifications included no cognitive impairment, mild cognitive impairment, and probable dementia. This thorough approach enabled the collection of reliable data regarding the long-term cognitive impacts of varying blood pressure control strategies.

The findings unveiled by the study were impressive. Individuals within the intensive treatment group demonstrated a sustained lower incidence of cognitive impairments compared to their counterparts in the standard treatment group. Notably, they exhibited a significantly reduced rate of mild cognitive impairment, alongside a lower combined incidence of both mild cognitive impairment and probable dementia. This aspect of the research emphasizes not just a fleeting benefit, but a substantial, ongoing advantage to aggressive hypertension management.

Historically, the significance of blood pressure control has often centered on cardiovascular health. In 2015, results from the original SPRINT trial indicated that rigorous blood pressure management could diminish the incidence of cardiovascular diseases and dramatically reduce mortality risk by 30 to 40%. Given the pronounced success and positive outcomes observed, the SPRINT trial was terminated ahead of schedule. However, this early conclusion created some uncertainties regarding the definitive role of intensive blood pressure control in dementia cases, particularly as participants experienced reduced treatment durations compared to the initial study design expectations.

The SPRINT MIND study initially reported findings in 2019 that hinted at positive cognitive outcomes resulting from stringent blood pressure management. Those early results indicated a significantly decreased risk of developing mild cognitive impairment for participants enjoying intensive blood pressure control, with observed benefits extending up to five years after treatment cessation. The new findings from this updated analysis, however, extend that timeline considerably. It reveals that the cognitive benefits persist for at least seven years following the conclusion of intensive treatment.

Dr. David M. Reboussin, a key author of the study and a professor of biostatistics and data science at Wake Forest University School of Medicine, clarified the study’s impactful implications, stating that the results provide compelling evidence supporting the hypothesis that rigorous blood pressure management is a vital strategy for cognitive impairment prevention. This approach is particularly crucial given cognitive decline is a leading factor in diminished independence among older adults. By advocating for lower blood pressure targets, we can promote both improved quality of life and prolonged active life for individuals dealing with hypertension.

As we face an aging population, understanding the intersection between cardiovascular health and cognitive function becomes increasingly pertinent. The SPRINT MIND findings amplify existing literature underscoring the need for preventive healthcare strategies that target blood pressure management. As substantial resources are invested in understanding Alzheimer’s disease and other forms of dementia, blood pressure control emerges as a straightforward yet powerful intervention that can alter the trajectory of cognitive health for many individuals facing hypertension.

These results offer hope for millions, highlighting the potential for everyday medical practice to incorporate aggressive blood pressure management as a standard for preventive care. By prioritizing blood pressure control, healthcare professionals might significantly impact aging populations, ultimately mitigating the risks associated with cognitive decline. This paradigm shift would not only influence individual patient outcomes but could also provide broader public health benefits as we seek to reduce the overall burden of dementia-related conditions.

The scientific community remains vigilant as additional studies and long-term follow-ups will be necessary to fully understand the profound implications of this research on clinical practices. However, the trajectory laid out by SPRINT MIND sets a promising foundation that emphasizes preventive measures and highlights the importance of longitudinal studies in unraveling complex health challenges.

As we delve into this data-rich field, the integration of aggressive blood pressure management into cardiovascular care could reshape how we approach later-life health and cognitive resilience. The application of intensive treatment protocols might redefine expectations for patients with hypertension, carving pathways toward improved living conditions and preserving cognitive health within our aging societies.

In summary, the findings from this major study underscore the relationship between blood pressure regulation and cognitive health outcomes. They serve as a call to action for healthcare systems to prioritize thorough blood pressure management, championing strategies that not only uphold cardiovascular health but also imbue hope for cognitive longevity.

Subject of Research: Blood Pressure Management’s Effect on Cognitive Impairment
Article Title: Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT
News Publication Date: January 21, 2025
Web References: https://school.wakehealth.edu/
References: 10.1212/WNL.000000000021333
Image Credits: Not Provided

Keywords: Hypertension, Dementia, Cognitive Impairment, Blood Pressure Management, Cardiovascular Risk, Cognitive Health